Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Sometimes the U.S. Food and Drug Administration (FDA) runs ahead of schedule. In the case of this week’s two PDUFA dates, that was completely true. Here’s a look.
Swedish Orphan Biovitrum AB (Sobi) has received an $8 billion (68 billion kronor) cash buyout offer from Advent International, valuing its shares at SEK 235 each.
Novartis announced that it is discontinuing the trial in kidney transplant patients after conducting an interim analysis from its CIRRUS-1 trial of CFZ533 (iscalimab).
There were a fair number of clinical trial announcements last week. Here’s a look.
The Mu variation is the fifth strain to be designated as a “variant of interest” by the World Health Organization.
Shares of Forte Biosciences plunged more than 80% in premarket trading after the company announced failure to demonstrate statistical significance of Phase II atopic dermatitis trial.
Heading into the Labor Day weekend in the U.S., there’s still plenty of COVID-19 news. Here’s a look.
Lilly’s most recent legal woes come from a proposed class-action lawsuit filed on Wednesday, accusing the company of age bias.
The life sciences industry was well-represented, with a handful of names featured in the top 100.
Henceforth, all JAK-inhibiting drugs like AbbVie’s Rinvoq, Pfizer’s Xeljanz, and Lilly’s Olumiant, have been ordered to include a warning label on the medicine to be sold in the U.S.
The approval was built on data from the Phase III ASPEN trial that compared Brukinsa to ibrutinib in a total of 201 patients. Here’s more about the drug.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.